Publications by authors named "Julien Fourcade"

Claim this Profile
S
Such a long wait: Three-dimensional paediatric transoesophageal echocardiography finally arises.
Philippe Acar, Khaled Hadeed, Paul Vignaud, Pierrick Pyra, Aitor Guitarte, Julien Fourcade

Arch Cardiovasc Dis· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma.
Diwakar Davar, Hong Wang, Joe-Marc Chauvin, Ornella Pagliano, Julien J Fourcade

J Clin Oncol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD226 opposes TIGIT to disrupt Tregs in melanoma.
Julien Fourcade, Zhaojun Sun, Joe-Marc Chauvin, Mignane Ka, Diwakar Davar

JCI Insight· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015.
Vashisht G. Y. Nanda, Weiyi Peng, Patrick Hwu, Michael A. Davies, Gennaro Ciliberto, Julien Fourcade

J Transl Med· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
Joe-Marc Chauvin, Ornella Pagliano, Julien Fourcade, Zhaojun Sun, Hong Wang

J Clin Invest· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells.
Zhaojun Sun, Julien Fourcade, Ornella Pagliano, Joe-Marc Chauvin, Cindy Sander

Cancer Res· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines.
Julien Fourcade, Zhaojun Sun, Ornella Pagliano, Joe-Marc Chauvin, Cindy Sander

Cancer Res· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Strategies to reverse melanoma-induced T-cell dysfunction.
Julien Fourcade, Hassane M Zarour

Clin Dermatol· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1.
Julien Fourcade, Zhaojun Sun, Ornella Pagliano, Philippe Guillaume, Immanuel F Luescher

Cancer Res· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epitope hierarchy of spontaneous CD4+ T cell responses to LAGE-1.
Pavol Kudela, Zhaojun Sun, Julien Fourcade, Bratislav Janjic, John M Kirkwood

J Immunol· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients.
Julien Fourcade, Zhaojun Sun, Mourad Benallaoua, Philippe Guillaume, Immanuel F Luescher

J Exp Med· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human tumor antigen-specific helper and regulatory T cells share common epitope specificity but exhibit distinct T cell repertoire.
Julien Fourcade, Zhaojun Sun, Pavol Kudela, Bratislav Janjic, John M Kirkwood

J Immunol· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients.
Julien Fourcade, Pavol Kudela, Zhaojun Sun, Hongmei Shen, Stephanie R Land

J Immunol· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients.
Julien Fourcade, Pavol Kudela, Pedro A Andrade Filho, Bratislav Janjic, Stephanie R Land

J Immunother· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cross-reactive CD4+ T cells against one immunodominant tumor-derived epitope in melanoma patients.
Pavol Kudela, Bratislav Janjic, Julien Fourcade, Florence Castelli, Pedro Andrade

J Immunol· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spontaneous CD4+ T cell responses against TRAG-3 in patients with melanoma and breast cancers.
Bratislav Janjic, Pedro Andrade, Xiao-Fei Wang, Julien Fourcade, Christine Almunia

J Immunol· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro metabolism of the phosphatidylinositol 3-kinase inhibitor, wortmannin, by carbonyl reductase.
Julianne L Holleran, Julien Fourcade, Merrill J Egorin, Julie L Eiseman, Robert A Parise

Drug Metab Dispos· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis